KOL Insight

Datamonitor Healthcare Chronic Heart Failure KOL Interview – Germany

A German KOL discusses current marketed therapies and SGLT-2 inhibitors for chronic heart failure, as well as key unmet needs in this therapeutic area.

February 4, 2019

Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.

March 23, 2020

Ebola KOL Interview #1

So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.

November 2, 2014

Schizophrenia and Bipolar Disorder KOL Interview – Germany

This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

Human Papillomavirus (HPV) KOL Interview – Italy

A European-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

January 3, 2020

Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Midwest

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

June 30, 2020

Colorectal Cancer KOL Interview – US, Northeast

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.

May 23, 2022

Triple-Negative Breast Cancer KOL Interview – US

A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 3, 2019

Selexipag for Pulmonary Arterial Hypertension

$89.00

Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.

February 1, 2014

Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy

In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Follicular Lymphoma KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression as well as unmet needs are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, Tazverik, and mosunetuzumab.

June 11, 2021

Acute Myeloid Leukemia (AML) KOL Interview – UK

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

March 14, 2022

Post-EASL KOL Interview

Highlights KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK). Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ). Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens […]

May 29, 2015

Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

This interview covers the current treatment of multiple myeloma in the US, and the main areas of unmet need.

January 18, 2019

Key Questions in Immuno-Oncology

$1,099.00

This KOL survey answers key questions about current immunotherapy treatments and future trends in the immuno-oncology space.

August 8, 2018

MDS/AML KOL Interview

Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]

April 9, 2015

Pulmonary Hypertension KOL Interview – France

This interview with a France-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, Ventavis, Veletri, Flolan, Revatio, Letairis, INOpulse, and sotatercept.

July 21, 2022

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include the CAR-T therapy Breyanzi, reversible BTK inhibitors MK-1026 and pirtobrutinib, and the PI3K inhibitor TG-1303.

October 1, 2020

Type 1 Diabetes KOL Interview – UK

This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes.

January 8, 2020

Treatment of VTE – EU KOL Interview

This interview with an EU vascular physician explores the dynamics in the 5 major European markets regarding the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

November 4, 2015

Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

Triple Negative Breast Cancer KOL Interview

“It [Abraxane] is so easy to give. Women tolerate it so well. It works pretty good, it doesn’t work all the time, it works pretty well, and the patients don’t get so fatigued, they don’t have side effects, they don’t need premeds, and they rarely need to be boosted for white cells decrease. Whereas in the Eribulin, you know they’re gonna be coming back. It’s a pretty easy drug to give. Patients tolerate it fairly well… I use it [Abraxane] as first line and I go back to it. Even if I have somebody that progresses, if they’ve been off of it for a while, I will often even go back to it.”

February 9, 2016

Macitenan for Pulmonary Arterial Hypertension

$89.00

Macitentan is a novel dual endothelin receptor antagonist (ERA)

showing sustained receptor occupancy

March 1, 2014

Anemia in Chronic Kidney Disease KOL Interview – US, West Coast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.

June 30, 2020

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #2

This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.

February 6, 2019

Schizophrenia and Bipolar Disorder KOL Interview – US, Northeast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #1

This interview covers hepatocellular carcinoma treatment trends in the US. We discuss current treatment options including the recently approved Keytruda and Lenvima. Also disused are Phase III pipeline therapies Imfinzi and Tecentriq for the first-line setting, along with the potential of PD-1/PD-L1 therapies in the adjuvant setting.

February 6, 2019

Depression KOL Interview – US #2

A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.

March 2, 2021

Schizophrenia and Bipolar Disorder Payer Interview – US, South

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning schizophrenia and bipolar disorder, with a focus on oral antipsychotics and long-acting injectables.